Long-term efficacy of omalizumab in patients with conventional treatment-resistant vernal keratoconjunctivitis
Background: In vernal keratoconjunctivitis, traditional treatments are sometimes insufficient for symptom control; the results with omalizumab are promising in resistant cases. Case report: 15-year-old female adolescent with vernal keratoconjunctivitis who had received multiple ophthalmic treatment...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Colegio Mexicano de Inmunología Clínica y Alergia, A.C.
2018-07-01
|
| Series: | Revista Alergia México |
| Subjects: | |
| Online Access: | http://revistaalergia.mx/ojs/index.php/ram/article/view/292 |
| Summary: | Background: In vernal keratoconjunctivitis, traditional treatments are sometimes insufficient for symptom control; the results with omalizumab are promising in resistant cases.
Case report: 15-year-old female adolescent with vernal keratoconjunctivitis who had received multiple ophthalmic treatments, immunotherapy and systemic steroids with no clinical response. She attended a clinical immunology and allergy department where she was started on omalizumab 225 mg every 2 weeks. After 6 months, she showed a decrease in pruritus and photophobia; two years later, both papillae and Horner-Trantas dots had disappeared. She remained symptom-free, and the use of ophthalmic drugs was therefore reduced. The patient missed omalizumab application on 4 occasions; however, symptoms recurred, and the papillae reappeared, but remitted upon drug re-initiation.
Conclusion: There is a temporal relationship between omalizumab administration and ocular symptom control, with evidence of relapse upon discontinuation. |
|---|---|
| ISSN: | 0002-5151 2448-9190 |